Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND/AIMS: To identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD). METHODS: AURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA. We also examined the relationship between visual acuity outcomes and number of injections received. RESULTS: Analyses were performed using data from year 1 (n=1695) and year 2 completers (n=1184). Logistic analysis showed that baseline visual acuity score, age at start of therapy, number of ophthalmoscopies and optical coherence tomography (OCT) (combined) and number of injections (ranibizumab) were significant (p<0.05) prognostic factors for vision maintenance (loss <15 letters) or vision gain (≥15 letters). Patients who received >7 injections (in 1 year) or >14 injections (over 2 years) gained more letters and demonstrated greater vision maintenance (loss of <15 letters) than patients who received fewer injections. There was a significant (p<0.05) association between number of injections and national reimbursement schemes and OCT. CONCLUSIONS: A number of factors that are predictive of treatment outcomes in a real-life setting were identified. Notably, the decline of treatment benefits may be linked to number of injections and a failure to visit clinicians and receive OCT as required. These findings may be helpful in guiding ophthalmologist treatment decisions under limited time and financial constraints. TRIAL REGISTRATION NUMBER: NCT01447043.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387
Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels
Ablonczy, Z., Dahrouj, M., & Marneros, A. G. (2014) · The FASEB Journal · doi:10.1096/fj.13-248021 · Cited by 52
Hariprasad, S. M., Morse, L. S., Shapiro, H., Wong, P., & Tuomi, L. (2012) · Journal of Ophthalmology · doi:10.1155/2012/690641 · Cited by 20
Cited by
The Diagnosis and Treatment of Age-Related Macular Degeneration
Stahl, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0513 · Cited by 270
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Chakravarthy, U., Havilio, M., Syntosi, A., Pillai, N., Wilkes, E., Benyamini, G., Best, C., & Sagkriotis, A. (2021) · Eye · doi:10.1038/s41433-020-01354-4 · Cited by 131
Khanani, A. M., Skelly, A., Bezlyak, V., Griner, R., Torres, L. R., & Sagkriotis, A. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.09.009 · Cited by 96
Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F. (2016) · Ophthalmologica · doi:10.1159/000446819 · Cited by 10
Metadata
- Authors
- Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., Kim, K., & Sivaprasad, S.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2016-03-30
- Volume
- 100
- Issue
- 12
- Pages
- 1623-1628
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2319705424
- Cited by
- 124
- References
- 9
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. https://app.cochat.ai/papers/10.1136/bjophthalmol-2015-308166
- The paper
- Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., Kim, K., & Sivaprasad, S. (2016). Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2015-308166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.